[go: up one dir, main page]

MX369799B - Derivados de piridina macrociclicos. - Google Patents

Derivados de piridina macrociclicos.

Info

Publication number
MX369799B
MX369799B MX2016012994A MX2016012994A MX369799B MX 369799 B MX369799 B MX 369799B MX 2016012994 A MX2016012994 A MX 2016012994A MX 2016012994 A MX2016012994 A MX 2016012994A MX 369799 B MX369799 B MX 369799B
Authority
MX
Mexico
Prior art keywords
compounds
macrocylic
pyridine derivatives
inhibitory activity
present
Prior art date
Application number
MX2016012994A
Other languages
English (en)
Other versions
MX2016012994A (es
Inventor
Lieven Meerpoel
François Maria Sommen
Gaston Stanislas Marcella Diels
Marcel Viellevoye
Bruno Schoentjes
Wroblowski Berthold
Jean- Claude Berthelot Didier
Luc Aimé Versele Matthias
Willems Marc
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2016012994A publication Critical patent/MX2016012994A/es
Publication of MX369799B publication Critical patent/MX369799B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a derivados de pirimidina macrocíclicos sustituidos de fórmula (I) (ver Fórmula) en donde las variables tienen el significado definido en las reivindicaciones; los compuestos de acuerdo con la presente invención tienen actividad inhibidora de EF2K y opcionalmente también actividad inhibidora de Vps34; la invención también se refiere a procesos para preparar tales compuestos novedosos, a composiciones farmacéuticas que comprenden dichos compuestos como principio activo, así como al uso de dichos compuestos como medicamento.
MX2016012994A 2014-04-03 2015-04-02 Derivados de piridina macrociclicos. MX369799B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163442 2014-04-03
EP14183823 2014-09-05
PCT/EP2015/057401 WO2015150557A1 (en) 2014-04-03 2015-04-02 Macrocylic pyridine derivatives

Publications (2)

Publication Number Publication Date
MX2016012994A MX2016012994A (es) 2016-12-07
MX369799B true MX369799B (es) 2019-11-21

Family

ID=52781118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012994A MX369799B (es) 2014-04-03 2015-04-02 Derivados de piridina macrociclicos.

Country Status (22)

Country Link
US (1) US20170022201A1 (es)
EP (1) EP3126365B1 (es)
JP (1) JP6420362B2 (es)
KR (1) KR102390274B1 (es)
CN (1) CN106132964B (es)
AU (1) AU2015239100B2 (es)
BR (1) BR112016022700B1 (es)
CA (1) CA2942751C (es)
CL (1) CL2016002495A1 (es)
EA (1) EA029758B1 (es)
ES (1) ES2665797T3 (es)
IL (1) IL248001B (es)
MA (1) MA39823A (es)
MX (1) MX369799B (es)
MY (1) MY185500A (es)
NZ (1) NZ725406A (es)
PE (1) PE20161365A1 (es)
PH (1) PH12016501962B1 (es)
SG (1) SG11201608241UA (es)
UA (1) UA118120C2 (es)
WO (1) WO2015150557A1 (es)
ZA (1) ZA201606768B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049383A1 (en) 2015-09-24 2017-03-30 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
HRP20201400T1 (hr) 2016-02-19 2020-11-27 Sprint Bioscience Ab Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa
CN108884067B (zh) 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
BR112019017929A2 (pt) 2017-02-28 2020-05-19 Morphic Therapeutic Inc inibidores de integrina (alfa-v)(beta-6)
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
JP2020524701A (ja) * 2017-06-22 2020-08-20 サイクルニウム ファーマ インコーポレイテッド ピリジン含有大環状化合物ライブラリーならびにその製造および使用方法
LT3672962T (lt) 2017-08-23 2022-05-10 Sprint Bioscience Ab Morfolinilpiridono junginiai
TW202308996A (zh) 2017-08-23 2023-03-01 瑞典商斯普林特生物科技公司 吡啶基吡啶酮化合物
PT3672948T (pt) 2017-08-23 2022-11-07 Sprint Bioscience Ab Compostos de piridinamina-piridona e pirimidinamina-piridona
US11498919B2 (en) 2017-08-23 2022-11-15 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
ES3019404T3 (en) 2018-08-29 2025-05-20 Morphic Therapeutic Inc Integrin inhibitors
TW202115095A (zh) * 2019-08-16 2021-04-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN113845521B (zh) * 2021-08-31 2024-06-18 中原工学院 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413964B1 (en) * 2000-01-12 2002-07-02 Desolms S. Jane Inhibitors of prenyl-protein transferase
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
SG151288A1 (en) 2003-12-18 2009-04-30 Janssen Pharmaceutica Nv 3-cyano-quinoline derivatives with antiproliferative activity
ES2305887T3 (es) 2003-12-18 2008-11-01 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos.
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
ES2330789T3 (es) 2005-06-30 2009-12-15 Janssen Pharmaceutica Nv Anilino-piridinotriazinas ciclicas como inhibidores de gsk-3.
TWI525096B (zh) * 2005-11-16 2016-03-11 Ｃｔｉ生技製藥有限公司 氧連接之嘧啶衍生物
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
DK2283024T3 (da) * 2008-03-10 2013-08-05 Janssen Pharmaceutica Nv 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
JP2011522865A (ja) 2008-06-13 2011-08-04 ノバルティス アーゲー Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物

Also Published As

Publication number Publication date
CN106132964B (zh) 2019-07-19
PH12016501962A1 (en) 2017-01-09
ZA201606768B (en) 2018-11-28
KR102390274B1 (ko) 2022-04-22
SG11201608241UA (en) 2016-10-28
UA118120C2 (uk) 2018-11-26
EP3126365B1 (en) 2018-01-10
PH12016501962B1 (en) 2017-01-09
JP6420362B2 (ja) 2018-11-07
BR112016022700B1 (pt) 2022-01-11
EP3126365A1 (en) 2017-02-08
MX2016012994A (es) 2016-12-07
US20170022201A1 (en) 2017-01-26
CA2942751C (en) 2023-03-21
MA39823A (fr) 2018-01-09
WO2015150557A1 (en) 2015-10-08
PE20161365A1 (es) 2016-12-17
EA201692000A1 (ru) 2017-01-30
BR112016022700A2 (es) 2017-08-15
MY185500A (en) 2021-05-19
JP2017509685A (ja) 2017-04-06
KR20160140739A (ko) 2016-12-07
IL248001B (en) 2018-11-29
AU2015239100A1 (en) 2016-09-29
KR102390274B9 (ko) 2023-03-03
CA2942751A1 (en) 2015-10-08
AU2015239100B2 (en) 2019-06-27
CL2016002495A1 (es) 2017-02-24
NZ725406A (en) 2022-08-26
EA029758B1 (ru) 2018-05-31
CN106132964A (zh) 2016-11-16
ES2665797T3 (es) 2018-04-27

Similar Documents

Publication Publication Date Title
PH12016501963A1 (en) Macrocyclic pyrimidine derivatives
MX369799B (es) Derivados de piridina macrociclicos.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
PH12017501921A1 (en) Novel compounds
MY198472A (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MY203342A (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12016501462A1 (en) Neprilysin inhibitors
PH12018500626A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
TW201613864A (en) Novel compounds
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
MX2016012669A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.

Legal Events

Date Code Title Description
FG Grant or registration